Adaptimmune Therapeutics PLC ADAP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/15/24 EDT
1.24quote price arrow up+0.09 (+7.83%)
Volume
1,349,073
52 week range
0.42 - 2.05
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.24
  • 52 Week High2.05
  • 52 Week High Date03/08/24
  • 52 Week Low0.42
  • 52 Week Low Date11/21/23

Key Stats

  • Market Cap316.897M
  • Shares Out255.56M
  • 10 Day Average Volume0.78M
  • Dividend-
  • Dividend Yield-
  • Beta2.34
  • YTD % Change56.37

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.24
  • 52 Week High2.05
  • 52 Week High Date03/08/24
  • 52 Week Low0.42
  • 52 Week Low Date11/21/23
  • Market Cap316.897M
  • Shares Out255.56M
  • 10 Day Average Volume0.78M
  • Dividend-
  • Dividend Yield-
  • Beta2.34
  • YTD % Change56.37

RATIOS/PROFITABILITY

  • EPS (TTM)-0.52
  • P/E (TTM)-2.38
  • Fwd P/E (NTM)-4.12
  • EBITDA (TTM)-128.198M
  • ROE (TTM)-187.61%
  • Revenue (TTM)60.281M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-188.90%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/15/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Adaptimmune Therapeutics PLC

 

Profile

MORE
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that...
David Mott
Non-Executive Independent Chairman of the Board
Adrian Rawcliffe
Chief Executive Officer, Director
William Bertrand Jr., Esq.
Chief Operating Officer
Gavin Wood
Chief Financial Officer
Address
60 Jubilee Avenue, Milton Park
Abingdon
OX14 4RX
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
ALPN
Alpine Immune Sciences Inc
64.97+0.02+0.03%
CRNX
Crinetics Pharmaceuticals Inc
50.49+1.11+2.25%
NUVL
Nuvalent Inc
71.68+3.66+5.38%
KRYS
Krystal Biotech Inc
163.19+3.72+2.33%
MDGL
Madrigal Pharmaceuticals Inc
211.73+0.75+0.36%